study of medical treatment reactivity by the chemokine receptor (CXCR4)as 1st line treatment in patients with metastatic colorectal cancer

INTERVENTION: CXCR4‐CEC>=20 mFOLFOX6,Bevacizumab L‐OHP:85mg/m2 5‐FU(bolus):400mg/m2 l‐LV:200mg/m2 5‐FU(infusion):2,400mg/m2 Bevacizumab:5mg/m2 CXCR4‐CEC>=20 mFOLFOX6,Panitumumab L‐OHP:85mg/m2 5‐FU(bolus):400mg/m2 l‐LV:200mg/m2 5‐FU(infusion):2,400mg/m2 Panitumumab :6mg/m2 CXCR4‐CEC<20 mFOLFOX6,Bevacizumab L‐OHP:85mg/m2 5‐FU(bolus):400mg/m2 l‐LV:200mg/m2 5‐FU(infusion):2,400mg/m2 Bevacizumab:5mg/m2 CXCR4‐CEC<20 mFOLFOX6,Panitumumab L‐OHP:85mg/m2 5‐FU(bolus):400mg/m2 l‐LV:200mg/m2 5‐FU(infusion):2,400mg/m2 Panitumumab :6mg/m2 CONDITION: Colorectal Cancer PRIMARY OUTCOME: Progression‐free survival SECONDARY OUTCOME: Safety profile,; Overall survival,; Time‐to‐treatment‐failure ,; Overall Response Rate INCLUSION CRITERIA: 1)Histologically proved Colon cancer or rectalcancer 2) KRAS wild‐type 3) measurable lesion 4) Age:20 to 80years 5) ECOG performance status of 0, 1 or 2 6) Expected survival >=3 months 7)Signed informed consent of the patient for registration 8) Adequate organ functions as listed below (at <=14 days prior to enrollment) WBC:4,000/mm3 to 12,000/mm3 Neutrophl: 2,000/mm3 to 6,000/mm3 Plt: >=100,000/mm3 Hb: >=9.0g/dL Total bilirubin <= upper limit of normal (ULN)*1.5 AST ,ALT and ALP <= upper limit of normal (ULN)*2.5 Serum creatinine <=upper limit of normal (ULN)*1.5